Tolvapton MED direct
Ended Awarded Last action
- Contract number
- 36C24122N0048
- Awardee
-
Otsuka America Pharmaceutical Inc. UEI QKABLBMA8FT9
- Awarding agency
-
Veterans Integrated Service Network 1
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $123,816
Award facts
- Contract value 100% obligated
- $123,851.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Pittsburgh, PA 15275, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$685 | |
| Original award | $124,500 |
About this award
Otsuka America Pharmaceutical Inc. received a delivery order contract valued at approximately $123.9K from Veterans Integrated Service Network 1 (VISN 1) for Tolvaptan medication, awarded on October 1, 2021, with completion targeted for September 30, 2022. The contract represents a firm fixed-price procurement with no set-aside designation and falls under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). Tolvaptan, marketed as Jynarque, is a specialty pharmaceutical product used to treat autosomal dominant polycystic kidney disease and hyponatremia, conditions affecting veteran populations served by the Department of Veterans Affairs' Veterans Health Administration.
This delivery order derives from Otsuka America's larger Blanket Purchase Agreement (BPA) with the VA's National Acquisition Center, a comprehensive $83.3M vehicle for Jynarque supply across multiple VISNs through March 2026. The BPA structure enables efficient procurement of critical pharmaceutical treatments by VA medical facilities nationwide, streamlining access to this specialized medication for veterans requiring treatment. Otsuka America's established federal pharmaceutical supply capabilities, evidenced by its $396M Federal Supply Schedule contract and multiple regional delivery orders, position the company as a primary supplier of complex therapeutic drugs to the Veterans Health Administration.
Quick answers
Who was awarded contract 36C24122N0048?
36C24122N0048 was awarded to Otsuka America Pharmaceutical Inc. by Veterans Integrated Service Network 1 (Veterans Health Administration) on October 1, 2021.
How much is contract 36C24122N0048 worth?
The government has obligated $123,816 on 36C24122N0048. Its current value, with exercised options, is $123,852.
Is contract 36C24122N0048 an order under another contract?
Yes. 36C24122N0048 is a delivery order under 36F79720D0099, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24122N0048 competed?
The extent of competition for 36C24122N0048 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award